Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formation

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Huang, Sheng Teng ^a   Yang, Rong Chi ^b   Wu, Hsiao Ting ^a   Wang, Chao Nin ^b   Pang, Jong Hwei S ^c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHLORIDE; CELL MEMBRANE PROTEIN; ELLAGIC ACID; GELATINASE A; MAGNESIUM CHLORIDE; MESSENGER RNA; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; UNCLASSIFIED DRUG; ZINC CHLORIDE; CHELATING AGENT; ZINC;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CHELATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; ULTRAVIOLET SPECTROPHOTOMETRY; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ZYMOGRAPHY; CELL CULTURE; CELL MOTION; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; CHELATING AGENTS; ELLAGIC ACID; ENZYME ACTIVATION; HUMANS; MATRIX METALLOPROTEINASE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ZINC;

EID: 79955757511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018986     Document Type: Article

References (37)

1. Hannum SM, (2004) Potential impact of strawberries on human health: A review of the science. Crit Rev Food Sci Nutr 44: 1-17.
2. Herrera MC, Luque De Castro MD, (2004) Ultrasound-assisted extraction for the analysis of phenolic compounds in strawberries. Anal Bioanal Chem 379: 1106-1112.
3. Yilmaz Y, Toledo RT, (2004) Major flavonoids in grape seeds and skins: Antioxidant capacity of catechin, epicatechin, and gallic acid. J Agric Food Chem 52: 255-260.
4. Saleem A, Husheem M, Harkonen P, Pihlaja K, (2002) Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula Retz. fruit. J Ethnopharmacol 81: 327-336.
5. Mertens-Talcott SU, Talcott ST, Percival SS, (2003) Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. J Nutr 133: 2669-2674.
6. Festa F, Aglitti T, Duranti G, Ricordy R, Perticone P, et al. (2001) Strong antioxidant activity of ellagic acid in mammalian cells in vitro revealed by the comet assay. Anticancer Res 21: 3903-3908.
7. Chakraborty S, Roy M, Bhattacharya RK, (2004) Prevention and repair of DNA damage by selected phytochemicals as measured by single cell gel electrophoresis. J Environ Pathol Toxicol Oncol 23: 215-226.
8. Anderson KJ, Teuber SS, Gobeille A, Cremin P, Waterhouse AL, et al. (2001) Walnut polyphenolics inhibit in vitro human plasma and LDL oxidation. J Nutr 131: 2837-2842.
9. Buniatian GH, (2003) Stages of activation of hepatic stellate cells: Effects of ellagic acid, an inhibitor of liver fibrosis, on their differentiation in culture. Cell Prolif 36: 307-319.
10. Narayanan BA, Re GG, (2001) IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid. Anticancer Res 21: 359-364.
11. Narayanan BA, Narayanan NK, Stoner GD, Bullock BP, (2002) Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci 7: 1821-1839.
12. Rumjahn SM, Javed MA, Wong N, Law WE, Buxton IL, (2007) Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer 97: 1372-1380.
13. Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, et al. (2005) Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 26: 821-826.
14. Forkman J, (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71.
15. Ispanovic E, Serio D, Haas TL, (2008) Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation. Am J Physiol Cell Physiol 295: C600-610.
16. Ingber DE, Prusty D, Frangioni JV, Cragoe EJ Jr, Lechene C, et al. (1990) Control of intracellular pH and growth by fibronectin in capillary endothelial cells. J Cell Biol 110: 1803-1811.
17. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner M, et al. (2001) Cooperetive interactions of laminin 5 gamma 2 chain, matrix metaloproteinnase-2, and membrane type-1- matrix/meteloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61: 6322-6327.
18. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, et al. (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficienct mice. Cancer Res 58: 1048-1051.
19. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, et al. (2003) RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 22: 167-175.
20. Yoon SO, Park SJ, Yun CH, Chung AS, (2003) Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36: 128-137.
21. Huang ST, Wang CY, Yang RC, Wu HT, Yang SH, et al. (2009) Ellagic acid, the active compound of Phyllanthus urinaria, exerts in vivo anti-angiogenic effect and inhibits MMP-2 activity. Evid Based Complement Alternat Med [Epub ahead of print] doi:10.1093/ecam/nep207.
22. Innocenti A, Beyza Oztürk Sarikaya S, Gülçin I, Supuran CT, (2010) Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem 18: 2159-2164.
23. Bock PE, Srinivasan KR, Shore JD, (1981) Activation of intrinsic blood coagulation by ellagic acid: insoluble ellagic acid-metal ion complexes are the activating species. Biochemistry 20: 7258-7266.
24. Span PN, Sweep CG, Manders P, Beex LV, Leppert D, et al. (2003) Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97: 2710-2715.
25. Talbot DC, Brown PD, (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A: 2528-2533.
26. Rosenblum G, Meroueh SO, Kleifeld O, Brown S, Singson SP, et al. (2003) Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2). J Biol Chem 278: 27009-27015.
27. Raffetto JD, Khalil RA, (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75: 346-359.
28. Richardson S, Neama G, Phillips T, Bell S, Carter SD, et al. (2003) Molecular characterization and partial cDNA cloning of facilitative glucose transporters expressed in human articular chondrocytes; stimulation of 2-deoxyglucose uptake by IGF-I and elevated MMP-2 secretion by glucose deprivation. Osteoarthritis Cartilage 11: 92-101.
29. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, et al. (2009) Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 9: 20.
30. Marks PA, (2010) Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochim Biophys Acta [June Epub ahead of print] doi:10.1016/j.bbagrm.2010.05.008.
31. Marks PA, (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066.
32. Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, et al. (2010) A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 103: 12-17.
33. Clark JC, Thomas DM, Choong PF, Dass CR, (2007) RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 26: 675-683.
34. Liu LT, Chang HC, Chiang LC, Hung WC, (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63: 3069-3072.
35. Gopalakrishna R, Gundimeda U, (2002) Antioxidant regulation of protein kinase C in cancer prevention. J Nutr 132: 3819S-3823S.
36. Ma Q, Cavallin LE, Yan B, Zhu S, Duran EM, et al. (2009) Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci USA 106: 8683-8688.
37. Chomczynski P, Sacchi N, (1987) Single-step method of RNA isolated by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.